nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—Rhinitis allergic—Varenicline—nicotine dependence	0.0688	0.0767	CcSEcCtD
Salmeterol—Respiratory tract congestion—Varenicline—nicotine dependence	0.0428	0.0477	CcSEcCtD
Salmeterol—Hoarseness—Varenicline—nicotine dependence	0.0355	0.0396	CcSEcCtD
Salmeterol—Myositis—Varenicline—nicotine dependence	0.0319	0.0355	CcSEcCtD
Salmeterol—Sinus congestion—Varenicline—nicotine dependence	0.0314	0.035	CcSEcCtD
Salmeterol—Throat irritation—Varenicline—nicotine dependence	0.031	0.0345	CcSEcCtD
Salmeterol—Sleep disturbance—Varenicline—nicotine dependence	0.0279	0.0311	CcSEcCtD
Salmeterol—Toothache—Varenicline—nicotine dependence	0.0257	0.0286	CcSEcCtD
Salmeterol—Upset stomach—Varenicline—nicotine dependence	0.0238	0.0266	CcSEcCtD
Salmeterol—Rhinorrhoea—Varenicline—nicotine dependence	0.0193	0.0215	CcSEcCtD
Salmeterol—Dysphonia—Varenicline—nicotine dependence	0.019	0.0212	CcSEcCtD
Salmeterol—Endocrine disorder—Varenicline—nicotine dependence	0.0188	0.021	CcSEcCtD
Salmeterol—Tenderness—Varenicline—nicotine dependence	0.0179	0.02	CcSEcCtD
Salmeterol—Chest discomfort—Varenicline—nicotine dependence	0.0177	0.0197	CcSEcCtD
Salmeterol—Viral infection—Varenicline—nicotine dependence	0.0173	0.0193	CcSEcCtD
Salmeterol—Musculoskeletal pain—Varenicline—nicotine dependence	0.0158	0.0176	CcSEcCtD
Salmeterol—Sleep disorder—Varenicline—nicotine dependence	0.0131	0.0146	CcSEcCtD
Salmeterol—Eczema—Varenicline—nicotine dependence	0.0126	0.0141	CcSEcCtD
Salmeterol—Injury—Varenicline—nicotine dependence	0.0123	0.0138	CcSEcCtD
Salmeterol—Atrial fibrillation—Varenicline—nicotine dependence	0.012	0.0133	CcSEcCtD
Salmeterol—Migraine—Varenicline—nicotine dependence	0.0112	0.0124	CcSEcCtD
Salmeterol—Irritability—Varenicline—nicotine dependence	0.0108	0.0121	CcSEcCtD
Salmeterol—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0104	0.101	CbGpPWpGaD
Salmeterol—Abdominal pain upper—Varenicline—nicotine dependence	0.0104	0.0115	CcSEcCtD
Salmeterol—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.0103	0.1	CbGpPWpGaD
Salmeterol—Cramp muscle—Varenicline—nicotine dependence	0.0102	0.0114	CcSEcCtD
Salmeterol—Nasopharyngitis—Varenicline—nicotine dependence	0.0101	0.0113	CcSEcCtD
Salmeterol—Asthma—Varenicline—nicotine dependence	0.0098	0.0109	CcSEcCtD
Salmeterol—Bronchitis—Varenicline—nicotine dependence	0.00943	0.0105	CcSEcCtD
Salmeterol—Abdominal discomfort—Varenicline—nicotine dependence	0.0094	0.0105	CcSEcCtD
Salmeterol—Hyperglycaemia—Varenicline—nicotine dependence	0.00884	0.00985	CcSEcCtD
Salmeterol—Infestation—Varenicline—nicotine dependence	0.00874	0.00974	CcSEcCtD
Salmeterol—Infestation NOS—Varenicline—nicotine dependence	0.00874	0.00974	CcSEcCtD
Salmeterol—Conjunctivitis—Varenicline—nicotine dependence	0.0085	0.00947	CcSEcCtD
Salmeterol—Epistaxis—Varenicline—nicotine dependence	0.00824	0.00919	CcSEcCtD
Salmeterol—Sinusitis—Varenicline—nicotine dependence	0.0082	0.00914	CcSEcCtD
Salmeterol—Connective tissue disorder—Varenicline—nicotine dependence	0.00771	0.00859	CcSEcCtD
Salmeterol—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00742	0.0723	CbGpPWpGaD
Salmeterol—Cardiac disorder—Varenicline—nicotine dependence	0.00728	0.00811	CcSEcCtD
Salmeterol—Immune system disorder—Varenicline—nicotine dependence	0.00709	0.0079	CcSEcCtD
Salmeterol—Mediastinal disorder—Varenicline—nicotine dependence	0.00707	0.00788	CcSEcCtD
Salmeterol—Arrhythmia—Varenicline—nicotine dependence	0.00701	0.00781	CcSEcCtD
Salmeterol—Mental disorder—Varenicline—nicotine dependence	0.00687	0.00766	CcSEcCtD
Salmeterol—Malnutrition—Varenicline—nicotine dependence	0.00683	0.00761	CcSEcCtD
Salmeterol—Back pain—Varenicline—nicotine dependence	0.00661	0.00736	CcSEcCtD
Salmeterol—Muscle spasms—Varenicline—nicotine dependence	0.00657	0.00732	CcSEcCtD
Salmeterol—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00643	0.0626	CbGpPWpGaD
Salmeterol—Tremor—Varenicline—nicotine dependence	0.0064	0.00713	CcSEcCtD
Salmeterol—Ill-defined disorder—Varenicline—nicotine dependence	0.00634	0.00706	CcSEcCtD
Salmeterol—Agitation—Varenicline—nicotine dependence	0.00628	0.00699	CcSEcCtD
Salmeterol—Angioedema—Varenicline—nicotine dependence	0.00624	0.00695	CcSEcCtD
Salmeterol—Malaise—Varenicline—nicotine dependence	0.00616	0.00686	CcSEcCtD
Salmeterol—Palpitations—Varenicline—nicotine dependence	0.00604	0.00673	CcSEcCtD
Salmeterol—Cough—Varenicline—nicotine dependence	0.00596	0.00664	CcSEcCtD
Salmeterol—Hypertension—Varenicline—nicotine dependence	0.0059	0.00657	CcSEcCtD
Salmeterol—Chest pain—Varenicline—nicotine dependence	0.00581	0.00648	CcSEcCtD
Salmeterol—Arthralgia—Varenicline—nicotine dependence	0.00581	0.00648	CcSEcCtD
Salmeterol—Myalgia—Varenicline—nicotine dependence	0.00581	0.00648	CcSEcCtD
Salmeterol—Anxiety—Varenicline—nicotine dependence	0.00579	0.00646	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00577	0.00644	CcSEcCtD
Salmeterol—Discomfort—Varenicline—nicotine dependence	0.00574	0.0064	CcSEcCtD
Salmeterol—Dry mouth—Varenicline—nicotine dependence	0.00569	0.00634	CcSEcCtD
Salmeterol—Oedema—Varenicline—nicotine dependence	0.00557	0.00621	CcSEcCtD
Salmeterol—Infection—Varenicline—nicotine dependence	0.00554	0.00617	CcSEcCtD
Salmeterol—Nervous system disorder—Varenicline—nicotine dependence	0.00547	0.00609	CcSEcCtD
Salmeterol—Tachycardia—Varenicline—nicotine dependence	0.00544	0.00606	CcSEcCtD
Salmeterol—Skin disorder—Varenicline—nicotine dependence	0.00541	0.00603	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00508	0.00566	CcSEcCtD
Salmeterol—Insomnia—Varenicline—nicotine dependence	0.00504	0.00562	CcSEcCtD
Salmeterol—Dyspnoea—Varenicline—nicotine dependence	0.00497	0.00554	CcSEcCtD
Salmeterol—Dyspepsia—Varenicline—nicotine dependence	0.00491	0.00547	CcSEcCtD
Salmeterol—Fatigue—Varenicline—nicotine dependence	0.00481	0.00536	CcSEcCtD
Salmeterol—Constipation—Varenicline—nicotine dependence	0.00477	0.00531	CcSEcCtD
Salmeterol—Pain—Varenicline—nicotine dependence	0.00477	0.00531	CcSEcCtD
Salmeterol—Feeling abnormal—Varenicline—nicotine dependence	0.00459	0.00512	CcSEcCtD
Salmeterol—Gastrointestinal pain—Varenicline—nicotine dependence	0.00456	0.00508	CcSEcCtD
Salmeterol—Urticaria—Varenicline—nicotine dependence	0.00443	0.00493	CcSEcCtD
Salmeterol—Abdominal pain—Varenicline—nicotine dependence	0.00441	0.00491	CcSEcCtD
Salmeterol—Body temperature increased—Varenicline—nicotine dependence	0.00441	0.00491	CcSEcCtD
Salmeterol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00426	0.0415	CbGpPWpGaD
Salmeterol—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00421	0.041	CbGpPWpGaD
Salmeterol—Hypersensitivity—Varenicline—nicotine dependence	0.00411	0.00458	CcSEcCtD
Salmeterol—Asthenia—Varenicline—nicotine dependence	0.004	0.00446	CcSEcCtD
Salmeterol—Diarrhoea—Varenicline—nicotine dependence	0.00381	0.00425	CcSEcCtD
Salmeterol—Dizziness—Varenicline—nicotine dependence	0.00369	0.00411	CcSEcCtD
Salmeterol—Vomiting—Varenicline—nicotine dependence	0.00354	0.00395	CcSEcCtD
Salmeterol—Rash—Varenicline—nicotine dependence	0.00351	0.00392	CcSEcCtD
Salmeterol—Dermatitis—Varenicline—nicotine dependence	0.00351	0.00391	CcSEcCtD
Salmeterol—Headache—Varenicline—nicotine dependence	0.00349	0.00389	CcSEcCtD
Salmeterol—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00346	0.0337	CbGpPWpGaD
Salmeterol—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00345	0.0336	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—DRD2—nicotine dependence	0.00334	0.0325	CbGpPWpGaD
Salmeterol—Nausea—Varenicline—nicotine dependence	0.00331	0.00369	CcSEcCtD
Salmeterol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00308	0.03	CbGpPWpGaD
Salmeterol—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00304	0.0296	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00281	0.0273	CbGpPWpGaD
Salmeterol—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00267	0.026	CbGpPWpGaD
Salmeterol—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00264	0.0257	CbGpPWpGaD
Salmeterol—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0025	0.0243	CbGpPWpGaD
Salmeterol—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00216	0.0211	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00195	0.019	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.00184	0.0179	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00181	0.0176	CbGpPWpGaD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00143	0.014	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00141	0.0138	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00141	0.0137	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00138	0.0134	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00133	0.0129	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00131	0.0127	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00122	0.0119	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00116	0.0113	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00115	0.0112	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00113	0.011	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000892	0.00868	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00078	0.00759	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000764	0.00744	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000708	0.00689	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000655	0.00638	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000645	0.00628	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000617	0.00601	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—FGD1—nicotine dependence	0.000612	0.00596	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000609	0.00593	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—OPRM1—nicotine dependence	0.000582	0.00566	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—FGD1—nicotine dependence	0.000556	0.00541	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000552	0.00538	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—DRD2—nicotine dependence	0.000421	0.00409	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TAS2R16—nicotine dependence	0.000418	0.00407	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—OPRM1—nicotine dependence	0.000329	0.0032	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGD1—nicotine dependence	0.000328	0.0032	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2A7—nicotine dependence	0.000314	0.00306	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—OPRM1—nicotine dependence	0.000299	0.00291	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKR1B10—nicotine dependence	0.00029	0.00282	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—DRD2—nicotine dependence	0.000238	0.00231	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000227	0.00221	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—DRD2—nicotine dependence	0.000216	0.0021	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—WASF2—nicotine dependence	0.000204	0.00199	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000197	0.00191	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—WASF1—nicotine dependence	0.000196	0.00191	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—OPRM1—nicotine dependence	0.000176	0.00172	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DRD2—nicotine dependence	0.000127	0.00124	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000106	0.00103	CbGpPWpGaD
